Indaptus Therapeutics (INDP) said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.
The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.
The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.
Shares of the company were down 1.3% in recent trading.
Price: 0.89, Change: -0.01, Percent Change: -1.33
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。